Business Description
![Eli Lilly and Co Eli Lilly and Co logo](https://static.gurufocus.com/logos/0C000007E3.png?14)
Eli Lilly and Co
NAICS : 325412
SIC : 2834
ISIN : US5324571083
Share Class Description:
LLY: Ordinary SharesCompare
Compare
Traded in other countries / regions
LLY.USALLY.CanadaLILY34.BrazilLLY.GermanyLLY.ArgentinaLLY.Mexico1LLY.ItalyLLYC.AustriaLLY.SwitzerlandLLY.BulgariaLLY.FranceLEL.UK IPO Date
1970-07-09Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.2 | |||||
Debt-to-Equity | 2.05 | |||||
Debt-to-EBITDA | 2.71 | |||||
Interest Coverage | 21.4 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 11.27 | |||||
Beneish M-Score | -1.87 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12 | |||||
3-Year EBITDA Growth Rate | -1 | |||||
3-Year EPS without NRI Growth Rate | 0.8 | |||||
3-Year Book Growth Rate | 24.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | 62.63 | |||||
Future 3-5Y Total Revenue Growth Rate | 20.5 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 87.49 | |||||
9-Day RSI | 85.39 | |||||
14-Day RSI | 79.31 | |||||
6-1 Month Momentum % | 34.61 | |||||
12-1 Month Momentum % | 71.99 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.35 | |||||
Quick Ratio | 1.03 | |||||
Cash Ratio | 0.14 | |||||
Days Inventory | 267.46 | |||||
Days Sales Outstanding | 81.64 | |||||
Days Payable | 122.85 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.55 | |||||
Dividend Payout Ratio | 0.48 | |||||
3-Year Dividend Growth Rate | 15.2 | |||||
Forward Dividend Yield % | 0.59 | |||||
5-Year Yield-on-Cost % | 1.11 | |||||
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | -0.12 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 80.16 | |||||
Operating Margin % | 33.51 | |||||
Net Margin % | 17.08 | |||||
FCF Margin % | -10.84 | |||||
ROE % | 53.79 | |||||
ROA % | 10.45 | |||||
ROIC % | 22.81 | |||||
ROC (Joel Greenblatt) % | 63.55 | |||||
ROCE % | 21.26 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 132.57 | |||||
Forward PE Ratio | 64.56 | |||||
PE Ratio without NRI | 90.5 | |||||
Shiller PE Ratio | 166.89 | |||||
PEG Ratio | 8.46 | |||||
PS Ratio | 22.23 | |||||
PB Ratio | 65.65 | |||||
Price-to-Tangible-Book | 757.71 | |||||
Price-to-Operating-Cash-Flow | 217.02 | |||||
EV-to-EBIT | 106.45 | |||||
EV-to-Forward-EBIT | 58.18 | |||||
EV-to-EBITDA | 89.25 | |||||
EV-to-Forward-EBITDA | 53.26 | |||||
EV-to-Revenue | 24.07 | |||||
EV-to-Forward-Revenue | 19.95 | |||||
EV-to-FCF | -221.96 | |||||
Price-to-Projected-FCF | 15.51 | |||||
Price-to-Median-PS-Value | 3.92 | |||||
Price-to-Peter-Lynch-Fair-Value | 9.66 | |||||
Price-to-Graham-Number | 55.21 | |||||
Earnings Yield (Greenblatt) % | 0.94 | |||||
FCF Yield % | -0.46 | |||||
Forward Rate of Return (Yacktman) % | 9.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:LLY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 35,932.1 | ||
EPS (TTM) ($) | 6.676 | ||
Beta | 0.58 | ||
Volatility % | 27.27 | ||
14-Day RSI | 79.31 | ||
14-Day ATR ($) | 17.839114 | ||
20-Day SMA ($) | 834.3865 | ||
12-1 Month Momentum % | 71.99 | ||
52-Week Range ($) | 434.34 - 892.2 | ||
Shares Outstanding (Mil) | 950.41 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Eli Lilly and Co Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Eli Lilly and Co Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(LLY)'s stock price today?
The current price of LLY is $885.01. The 52 week high of LLY is $892.20 and 52 week low is $434.34.
When is next earnings date of Eli Lilly and Co(LLY)?
The next earnings date of Eli Lilly and Co(LLY) is 2024-08-08.
Does Eli Lilly and Co(LLY) pay dividends? If so, how much?
The Dividend Yield %  of Eli Lilly and Co(LLY) is 0.55% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(LLY) was 1.96. The lowest was 0.45. And the median was 0.56. The  Forward Dividend Yield % of Eli Lilly and Co(LLY) is 0.59%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |